The former home of a biopharmaceutical plant in Boulder may soon be repurposed.
AGC Biologics has announced its purchase of the 330,000 square foot facility that once belonged to the Astra Zeneca company, with plans to spend upwards of $100 million on transforming the building.
The structure, sitting on just over 20 acres, was built in 1991.
Located at 5550 Airport Boulevard on the northeast side of Boulder, the building has been vacant for more than a year after Astra Zeneca shuttered it in a company-wide consolidation effort.
In a statement, Patricio Massera, chief executive officer with AGC Biologics, said the acquisition of the Boulder plant will support “AGC Biologics’ company-wide expansion initiative.”
That initiative, continued Massera, is designed to “support our customers’ demand for mammalian projects, now and into the future.”
More specifically, once the facility undergoes a major re-tooling, it will make it possible for AGC Biologics to advance the “development, manufacturing and commercial functions within our global company.”
Based in Soborg, Denmark, AGC Biologics specializes in the development and manufacture of pre-clinical to commercial biopharmaceuticals.
The company already has facilities up and running in Chiba, Japan; Heidelberg, Germany; Copenhagen, Denmark; and Seattle.
Work to re-purpose the Boulder facility is expected to begin sometime later this summer, with an anticipated completion date of spring 2021.
By Garry Boulard
